October has been recognized worldwide for years as Breast Cancer Awareness Month. As part of this campaign, October 15 marks European Breast Cancer Day, symbolized by the pink ribbon. Breast cancer is the most commonly diagnosed cancer among women globally, accounting for 25% of all cases and one of the leading causes of death (14%). Women diagnosed with breast cancer make up 36% of all cancer patients. Every year, nearly 1.7 million women receive this diagnosis, and over 500,000 die from the disease. [1]
The highest breast cancer incidence rates are observed in developed countries such as Belgium, Denmark, the Netherlands, Germany, and the United Kingdom, while the lowest rates occur in regions of Africa and Southeast Asia. The geographical context significantly influences the risk of developing breast cancer. For example, Japanese women who emigrate to the United States begin to have breast cancer risks that approach those observed in their new place of residence, suggesting that environmental factors also play a crucial role.
In Poland, approximately 20,000 women are diagnosed with breast cancer each year. This means that an average of 55 new cases are diagnosed daily. Unfortunately, the breast cancer mortality rate in Poland is about 6.5 per 100,000 women per year, placing us among the leaders in Europe. In 2020, around 6,500 women died from this cancer. [2]
Survival rates for breast cancer are also concerning. The five-year survival rate for women with breast cancer in Poland is about 87%, which is lower compared to Western European countries, where this rate exceeds 90%.
Prevention plays a key role in the fight against breast cancer. Unfortunately, only about 40% of women in Poland undergo mammography within the recommended guidelines, which affects late diagnoses and poorer treatment outcomes. These statistics highlight the importance of early detection and prevention in combating breast cancer in Poland. It is worth investing in education and programs that encourage regular screenings to increase awareness and improve health statistics in our country.
Traditional diagnostic methods such as X-rays or ultrasounds have limitations in detecting cancer metastases. While these tests are valuable, their accuracy often falls short of modern techniques such as PET/CT or PET/MR, which offer higher sensitivity and specificity. PET/MR allows for simultaneous evaluation of the entire body with a lower dose of ionizing radiation than PET/CT.
What is breast magnetic resonance imaging?
Breast magnetic resonance imaging (MRI) is an advanced imaging method used to diagnose changes in breast tissues. This examination is often performed for preventive purposes regarding breast cancer and before planned surgeries. MRI allows for the detection of small changes that may be difficult to notice with other techniques, such as ultrasound.
Indications for performing breast MRI:
- Patients with a history of breast cancer.
- Individuals with BRCA1/BRCA2 gene mutations.
- Women with a family history of breast or ovarian cancer.
- Patients who have undergone mastectomy and those with breast implants.
Contraindications for breast MRI:
- Having metal implants, a pacemaker, or other electronic devices.
- Risk of burns in individuals with tattoos containing metallic pigments.
Preparation for the examination:
- For non-contrast MRI, no special preparations are required; however, comfortable clothing and the removal of metal objects are recommended.
- For contrast MRI, kidney function tests are necessary, and patients should arrive fasting.
What can be detected using breast MRI?
Breast MRI is effective in determining the stage of disease, the location of tumors, and monitoring treatment progress. It provides important information that can support breast cancer diagnostics, particularly in identifying metastases. With its high precision, MRI serves as a significant complement to traditional diagnostic methods, offering valuable data for therapeutic decision-making.
According to BIRADS guidelines, breast MRI can be performed on both 1.5T and 3T machines. However, the 3T machine provides a significant enhancement to traditional diagnostic methods, offering higher image resolution and better detection of small changes. This increased precision is crucial in breast cancer diagnostics. At BioSkaner, we have both options available, allowing us to tailor the examination to the individual needs of our patients.
PET/MR and PET/CT are modern imaging methods that combine cellular metabolism studies with information about organ structure. They enable early detection of breast cancer and precise assessment of its location and characteristics. Their advantages include high diagnostic precision, the ability to monitor treatment effectiveness, and better therapy planning.
BioSkaner is currently recruiting for a free scientific study aimed at women diagnosed with breast cancer (stage II2 or higher). This project offers free whole-body imaging, including PET/MR, PET/CT, and WBMR. It is a unique opportunity to access advanced diagnostic technologies. Participation in the project allows for precise assessment of cancer spread and the development of an optimal treatment plan. No more than 7 days will pass from qualification for the project to the first examination. Your health matters.
We encourage you to learn more about the recruitment for the free scientific study for breast cancer patients.
Current research projects
Sources
